This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Scholar Rock Holding (SRRK) is back in focus after updating investors on an FDA warning letter sent to its manufacturing partner, Catalent Indiana, along with plans to resubmit its biologics license ...

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology ...

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes ...

Histological sample of skeletal muscle tissue under a microscope. Veru is testing a muscle-building drug in combination with Novo Nordisk's Wegovy to improve body composition in people with obesity ...

Company plans to expand into cardiometabolic disorders, leveraging its experience in myostatin inhibition Preclinical data support advancing SRK-439, a novel investigational myostatin inhibitor for ...

Poster presentation to include new safety, efficacy, and biomarker data from the long-term expansion phase of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 “These ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and ...